Upstate Active Clinical Trials
Study Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm InfantsWhat is the purpose of the study? (in Layman's terms, please describe the study)
This study involves research for the purpose of seeing how effective REGN2222 is at reducing medical visits for RSV infection when it is administered intramuscularly (IM), by inserting a needle into the muscle.Upstate Institutional Review Board (IRB) Number:
770394Study/Protocol ID:
R2222-RSV-1332Study Phase:
Phase IIIPatient Age Group:
ChildrenPrincipal Investigator:
Joseph B DomachowskeWho can I contact for more information?
Name: Jodi Halczyn
Phone: 315-464-1992
Email: halczynj@upstate.edu